Pirfenidone: a guide to its use in idiopathic pulmonary fibrosis
Drugs & Therapy Perspectives, 06/04/2012
Keating GM et al. - In general, oral pirfenidone (Esbriet®) is associated with beneficial effects on forced vital capacity and the 6–minute walk test in patients with idiopathic pulmonary fibrosis. Pirfenidone has an acceptable tolerability profile in this population, with most adverse events being of mild to moderate severity.
